

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Jun 2026

Evaluation of the effect of high protein-weight loss diet combined with beta cryptoxanthin supplement on metabolic factors, serum levels of oxidants, inflammatory and adipocytokins among patients with nonalcoholic fatty liver disease.

Protocol summary

Summary

Nonalcoholic fatty liver disease (NAFLD) is one of the most common prevalent liver diseases, and associates with obesity, diabetes and insulin resistance (IR). Controversy exists regarding optimal macronutrient without energy restriction and beta - cryptoxanthin on NAFLD. The objective of this work is evaluation of the effect of high protein-weight loss diet combined with beta cryptoxanthin supplement on metabolic factors, serum levels of oxidants, inflammatory and adipocytokins among patients with nonalcoholic fatty liver disease. In this randomized, triple-blind, placebo-controlled clinical trial, ninety-two eligible patients, aged between 18-60 years, of both genders, alcohol consumption <20 g/day, serum ALT levels less than five times of the upper limit (maximum limit of 30 for women and 40 for men), lack of associated diseases and drugs with NAFLD will be randomly assign to 4 groups, label as Calorie restricted- high protein diet plus 6 mg beta cryptoxanthin (CR-HPD + β -CX) group, CR-HPD + placebo, Calorie restricted- normal protein diet plus 6mg beta cryptoxanthin (CR-NPD + β -CX) and CR-NPD + placebo (control group) for 3 months. Serum adiponectin and high sensitive-C-reactive protein (CRP) as primary outcomes will be measured.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017060210181N10**
Registration date: **2017-06-20, 1396/03/30**
Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2017-06-20, 1396/03/30

Registrant information

Name

Fatemeh Heidari

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 61 1373 8255

Email address

haidari-f@ajums.ac.ir

Recruitment status

Recruitment complete

Funding source

Ahvaz Jundishapur University of Medical Sciences

Expected recruitment start date

2017-09-23, 1396/07/01

Expected recruitment end date

2018-01-21, 1396/11/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of high protein-weight loss diet combined with beta cryptoxanthin supplement on metabolic factors, serum levels of oxidants, inflammatory and adipocytokins among patients with nonalcoholic fatty liver disease.

Public title

Evaluation of the effect of high protein-weight loss diet combined with beta cryptoxanthin supplement on nonalcoholic fatty liver disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria will be included: subjects will be overweight and obese ($25 \leq \text{BMI} \leq 40$) individuals aged between 18–60 years of both genders, existence of NAFLD by ultrasound, NAFLD activity score less than 3, and willingness to participate. subjects with viral hepatitis, cirrhosis, Wilson's disease, acute fatty liver of pregnancy, hepatocellular carcinoma, hypothyroidism and a history of chronic liver disease, lipodystrophy, menopause, parenteral nutrition, bladder and bile duct disease, significant weight loss ($\geq 10\%$ of body weight during 6 months ago) or weight loss surgery, Congenital metabolic diseases, subjects on antioxidant supplementations, milk thistle and omega-3 fatty acids in the 6 months ago, a history of liver damaging drugs (amiodarone, anti-virus, aspirin, non-steroidal anti-inflammatories, corticosteroids, methotrexate, tamoxifen, tetracycline, valproic acid), alcohol consumption >20 g/day, calorie intake less than 800 kcal or more than 4200 a day, pregnancy and lactation, serum ALT levels more than five times of the upper limit (maximum limit of 30 for women and 40 for men), history of cardiovascular and kidney disease (urine analysis Albumina ≥ 30 (mg / 24 h) and GFR ≤ 90 ml / min / 1.73 m²) will be not included.

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **92**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Triple blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ahvaz Jundishapur University of Medical Sciences

Street address

Ahvaz Jundishapur University of Medical Sciences

City

Ahvaz

Postal code**Approval date**

2017-05-20, 1396/02/30

Ethics committee reference number

IR.AJUMS.REC.1396.138

Health conditions studied**1****Description of health condition studied**

Nonalcoholic fatty liver disease

ICD-10 code

k75.8

ICD-10 code description

nonalcoholic steatohepatitis

Primary outcomes**1****Description**

Plasma insulin

Timepoint

before intervention and after 3 months intervention

Method of measurement

colorimetry

2**Description**

free fatty acids

Timepoint

before intervention and after 3 months intervention

Method of measurement

Eliza

3**Description**

serum beta cryptoxanthin

Timepoint

before intervention and after 3 months intervention

Method of measurement

HPLC- C18

4**Description**

serum adiponectin

Timepoint

before intervention and after 3 months intervention

Method of measurement

Eliza

5

Description

high sensitive-C-reactive protein (CRP)

Timepoint

before intervention and after 3 months intervention

Method of measurement

Eliza

Secondary outcomes

1

Description

weight

Timepoint

before intervention and after 3 months intervention

Method of measurement

electronic scale (Beurer PS160, Germany)

2

Description

BMI

Timepoint

before intervention and after 3 months intervention

Method of measurement

weight (kg)/height² (m²)

3

Description

body fat mass

Timepoint

before intervention and after 3 months intervention

Method of measurement

Bioelectrical impedance analysis (BIA)

4

Description

LDL

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

5

Description

HDL

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

6

Description

Total cholesterol

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

7

Description

triglyceride

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

8

Description

fasting blood sugar

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

9

Description

aspartate aminotransferase (AST)

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

10

Description

alanine aminotransferase (ALT)

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

11

Description

γ-glutamyl transferase (GGT)

Timepoint

before intervention and after 3 months intervention

Method of measurement

Enzymetic method

12

Description

malondialdehyde (MDA)

Timepoint

before intervention and after 3 months intervention

Method of measurement

Satoh

13

Description

model-insulin resistance index (HOMA-IR)

Timepoint

before intervention and after 3 months intervention

Method of measurement

HOMA= fasting serum insulin (μU/ml)× fasting plasma

glucose (mM/L)/22.5

14

Description

HbA1c

Timepoint

before intervention and after 3 months intervention

Method of measurement

spectrophotometry

Intervention groups

1

Description

Intervention group1 : reduction of calorie intake by 500 K cal/day and diet with 30% fat, 25% protein, and 45% carbohydrates (high-protein diet) plus 6 mg beta cryptoxanthin for 3 months

Category

Lifestyle

2

Description

Intervention group 2: reduction of calorie intake by 500 K cal/day and diet with 30% fat, 25% protein, and 45% carbohydrates (high-protein diet) plus placebo for 3 months

Category

Lifestyle

3

Description

Intervention group 3 : reduction of calorie intake by 500 K cal/day and diet with 30% fat, 15% protein, and 55% carbohydrates (normal protein diet) plus 6 mg beta cryptoxanthin for 3 months

Category

Lifestyle

4

Description

Control group : reduction of calorie intake by 500 K cal/day and diet with 30% fat, 15% protein, and 55% carbohydrates (normal protein diet) plus placebo for 3 months

Category

Lifestyle

Recruitment centers

1

Recruitment center

Name of recruitment center

Golestan Hospital of Ahvaz University

Full name of responsible person

Dr. Fatemeh Haidari

Street address

Ahvaz, Golestan hospital, Ahvaz Jundishapur University of Medical Sciences

City

Ahvaz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person

Dr. Behzad Sharif Makhmalzadeh

Street address

Ahvaz Jundishapur University of Medical Sciences, Golestan Highway, ahvaz, iran Ahvaz

City

Ahvaz

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz Jundishapur University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Science

Full name of responsible person

Dr. Fatemeh Heidari

Position

Associate Professor

Other areas of specialty/work

Street address

Golestan Ave. Dept. of Nutrition, School of Paramedical, Ahvaz Jundishapur University of Medical Science Ahvaz

City

Ahvaz

Postal code

Phone

+98 61 3373 8330

Fax

Email

Haidari58@gmail.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Science

Full name of responsible person

Dr. Fatemeh Heidari

Position

Associate Professor

Other areas of specialty/work**Street address**

Golestan Ave. Dept. of Nutrition, School of Paramedical, Ahvaz Jundishapur University of Medical Science Ahvaz

City

Ahvaz

Postal code**Phone**

+98 61 3373 8330

Fax**Email**

Haidari58@gmail.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Science

Full name of responsible person

Dr. Fatemeh Heidari

Position

Associate Professor

Other areas of specialty/work**Street address**

Golestan Ave. Dept. of Nutrition, School of Paramedical, Ahvaz Jundishapur University of Medical Science Ahvaz

City

Ahvaz

Postal code**Phone**

+98 61 3373 8330

Fax**Email**

Haidari58@gmail.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty